Marksans Pharma grants 3 lakh stock options at ₹10 each

1 min read Updated on 26 May 2026, 05:04 AM

Reviewed by

Shriram SScanX News Team

AI Summary

Marksans Pharma granted 3,00,000 stock options to eligible employees under its Marksans Employees Stock Option Scheme 2024 at an exercise price of ₹10 per option. The grant, approved by the Nomination and Remuneration Committee on May 25, 2026, covers equity shares with a face value of Re. 1 each and complies with SEBI regulations. The options vest one year from the grant date and remain exercisable for two years thereafter.

*this image is generated using AI for illustrative purposes only.

Marksans Pharma has granted 3,00,000 stock options to eligible employees under its Marksans Employees Stock Option Scheme 2024. The options, priced at ₹10 each, were approved by the company's Nomination and Remuneration Committee on May 25, 2026. This move follows shareholder approvals passed in September 2024 and August 2025, along with necessary nods from BSE Limited and National Stock Exchange of India Limited in September 2025.

The grant covers 3,00,000 equity shares with a face value of Re. 1 each. The scheme is compliant with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options will vest one year from the date of grant, following which employees can exercise them within a period of two years.

Key Details of the Grant

The disclosure regarding the ESOP was submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the options are not exercisable immediately and that no money has been realized at this stage.

S. No.	Disclosures	Particulars
A	Options Granted	3,00,000
C	Total Shares Covered	3,00,000 equity shares of Re. 1 each
D	Exercise Price	₹10 per option
F	Exercise Period	2 years from date of grant
L	Vesting Period	1 year from date of grant

The meeting to approve the grant commenced at 04:50 p.m. and concluded at 05:25 p.m. on May 25, 2026. Harshavardhan Panigrahi, Company Secretary & Compliance Officer, signed the disclosure on behalf of Marksans Pharma.

Historical Stock Returns for Marksans Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.17%	+14.71%	+31.05%	+30.30%	-1.02%	+229.50%

How does the company plan to address potential equity dilution if further ESOP grants are approved in the future?

What impact will the vesting of these options have on the company's retained earnings and financial statements in 2027?

Does this ESOP allocation signal a strategic shift towards talent retention in specific departments or geographies?

Regulatory Disclosure

The declaration was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The promoters confirmed that they have not made any encumbrance, directly or indirectly, of the shares held by them in Marksans Pharma Limited.

Submission Details

The communication was addressed to BSE Limited and the National Stock Exchange of India Limited on April 02, 2026. The document was signed by Mark Saldanha and Sandra Saldanha, the undersigned promoters of the company. A copy of the declaration was also marked to the Audit Committee of Directors.

Historical Stock Returns for Marksans Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.17%	+14.71%	+31.05%	+30.30%	-1.02%	+229.50%

How might Marksans Pharma's clean promoter shareholding structure influence institutional investor confidence and potential foreign portfolio investment in the coming quarters?

Could the unencumbered promoter holdings position Marksans Pharma favorably for future fundraising activities such as QIPs or strategic partnerships?

What are the broader implications for Marksans Pharma's corporate governance rating, and how might this affect its valuation multiples relative to peers in the mid-cap pharma space?